CILR investigators are committed to studying acute and chronic inflammation and lung diseases.

We have robust basic science and translational research interests, utilizing various approaches to determine the mechanisms of pathophysiological conditions. We aim to advance our understanding of diseases and develop innovative therapeutic interventions. By integrating molecular, cellular, and organ-level studies, we aim to enhance pre-clinical findings, which can lead to the improvement of patient outcomes. 

Key areas of focus include: 

Emphysema 
The Kosmider Lab studies this serious form of chronic obstructive pulmonary disease (COPD) often caused by smoking. Emphysema damages tiny air sacs in the lungs and makes it hard to breathe. Currently there aren’t many effective treatments. This lab looks for ways to keep lung cells healthy and help them repair the disease’s damage. Their goal is to find new treatments that can improve life for people with emphysema. 

Idiopathic pulmonary fibrosis (IPF) 
The Bahmed Lab studies this serious lung disease that causes scarring and makes it hard to breathe. IPF leads to gradual lung failure, and treatment options are limited, with lung transplants often the only way to extend life. The disease damages alveolar cells that normally help repair lung tissue. The lab uses human lung cells to explore how IPF develops and to find new targets for future treatments.  

Immune mechanisms in skin and barrier tissues 
The Jensen Lab’s goal is to deepen fundamental knowledge about how immune responses to infection in the skin and mucosal tissues start and how long-term protective immunity is maintained. Additionally, they investigate how these mechanisms can malfunction, leading to chronic inflammatory conditions such as allergies, eczema, and psoriasis.  

Sepsis 
The Kilpatrick Lab studies sepsis, a life-threatening reaction to infection that can damage organs. Research focuses on neutrophils, a type of immune cell, and how they interact with blood vessel cells during sepsis. Using tools like organ-on-chip models and computer simulations, the team aims to create personalized treatments based on how different neutrophil types respond in patients. 

G protein-coupled receptors (GPCRs) in the development and progression of COPD 
The Rogers Lab studies how G protein-coupled receptors (GPCRs) — proteins that help cells respond to signals — affect inflammation in severe COPD. Their research shows that advanced COPD leads to an abnormal buildup of aggressive immune cells in the lungs. They focus on chemokine, opioid, and formyl peptide receptors that play key roles in driving this harmful response.  

Defective airway epithelial regeneration and innate immune function  
The Sajjan Lab studies the airway epithelium, a layer of cells that acts as the first line of defense in the lungs. It plays a key role in the body’s innate immune response by blocking and clearing out harmful particles and germs. In diseases like COPD, asthma, and cystic fibrosis, this defense system becomes damaged and less effective. The lab is investigating why this happens and is testing potential treatments, including quercetin, a natural compound that has shown promise in improving lung health in COPD patients.